---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161592"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:17:10.989854+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024

## Summary
- Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.
- Strategic alternatives committee formed including Camac nominees; rights plan expires July 12, 2024, not renewed, no new plan for 3 years.
- Camac enters standstill/voting agreement through 2028; company pays $364k for Camac's 2023 proxy contest out-of-pocket expenses.
- Settlement resolves claims that July 2023 private placement (~$25M) was intended to entrench board and block Camac director nominees.
- The standstill prohibits Camac from acquiring additional shares, launching proxy contests, or seeking board representation until 2028.

## SEC filing metadata
- accession: 0001193125-24-161592
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524161592/0001193125-24-161592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524161592/d826178d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161592
- JSON: https://secwatch.observer/filing/0001193125-24-161592.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.